346 related articles for article (PubMed ID: 25058863)
1. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation.
Bruere H; Fauchier L; Bernard Brunet A; Pierre B; Simeon E; Babuty D; Clementy N
Am J Med; 2015 Jan; 128(1):30-7. PubMed ID: 25058863
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
[TBL] [Abstract][Full Text] [Related]
3. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Clementy N; Haguenoer K; Fauchier L; Lip GY
Am J Med; 2014 Oct; 127(10):972-8. PubMed ID: 24929021
[TBL] [Abstract][Full Text] [Related]
4. Hypothyroidism was 300% more frequent than hyperthyroidism in patients with atrial fibrillation enrolled over 10 years.
Chauhan V
Am J Med; 2015 Oct; 128(10):e51. PubMed ID: 26386994
[No Abstract] [Full Text] [Related]
5. Thyroid status, cardiovascular risk, and mortality in older adults.
Cappola AR; Fried LP; Arnold AM; Danese MD; Kuller LH; Burke GL; Tracy RP; Ladenson PW
JAMA; 2006 Mar; 295(9):1033-41. PubMed ID: 16507804
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment in the development of atrial fibrillation at patients with associate thyroid dysfunctions.
Tănase DM; Ionescu SD; Ouatu A; Ambăruş V; Arsenescu-Georgescu C
Rev Med Chir Soc Med Nat Iasi; 2013; 117(3):623-9. PubMed ID: 24502026
[TBL] [Abstract][Full Text] [Related]
7. Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism.
Lin YS; Tsai HY; Lin CY; Wu VC; Chen TH; Yang TY; Aboyans V; Chen MC
Glob Heart; 2021 Jun; 16(1):45. PubMed ID: 34211831
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
9. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.
Friberg L; Benson L; Lip GY
Eur Heart J; 2015 Feb; 36(5):297-306. PubMed ID: 24722803
[TBL] [Abstract][Full Text] [Related]
10. Thyroid diseases and cerebrovascular disease.
Squizzato A; Gerdes VE; Brandjes DP; Büller HR; Stam J
Stroke; 2005 Oct; 36(10):2302-10. PubMed ID: 16179578
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
[TBL] [Abstract][Full Text] [Related]
13. Effect of hyperthyroidism on the hypercoagulable state and thromboembolic events in patients with atrial fibrillation.
Chen Q; Yan Y; Zhang L; Cheng K; Liu Y; Zhu W
Cardiology; 2014; 127(3):176-82. PubMed ID: 24434544
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and adverse events in patients with incident atrial fibrillation.
Overvad TF; Rasmussen LH; Skjøth F; Overvad K; Lip GY; Larsen TB
Am J Med; 2013 Jul; 126(7):640.e9-17. PubMed ID: 23601271
[TBL] [Abstract][Full Text] [Related]
15. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation and hyperthyroidism: relation between transoesophageal markers of a thrombogenic milieu and clinical risk factors for thromboembolism.
Souza MV; Duarte MM; Coeli CM; Vaisman M
Clin Endocrinol (Oxf); 2012 Mar; 76(3):448-53. PubMed ID: 21950838
[TBL] [Abstract][Full Text] [Related]
17. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after ablation for typical atrial flutter (from the Loire Valley Atrial Fibrillation Project).
Clementy N; Desprets L; Pierre B; Lallemand B; Simeon E; Brunet-Bernard A; Babuty D; Fauchier L
Am J Cardiol; 2014 Nov; 114(9):1361-7. PubMed ID: 25200340
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial).
Goldstein SA; Green J; Huber K; Wojdyla DM; Lopes RD; Alexander JH; Vinereanu D; Wallentin L; Granger CB; Al-Khatib SM
Am J Cardiol; 2019 Nov; 124(9):1406-1412. PubMed ID: 31474328
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.
Darkow T; Vanderplas AM; Lew KH; Kim J; Hauch O
Curr Med Res Opin; 2005 Oct; 21(10):1583-94. PubMed ID: 16238898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
